Drug Database
AM

ammonium lactate

✓ Approved

Bristol-Myers Squibb · Small Molecule · Small Molecule

What is ammonium lactate?

ammonium lactate is a small molecule developed by Bristol-Myers Squibb. It is approved for therapeutic indications via unknown.

Drug Profile

CompanyBristol-Myers Squibb
Drug ClassSmall Molecule
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, Bristol-Myers Squibb

Therapeutic Indications

ammonium lactate is developed for 3 unique indications across 3 therapeutic areas.

Therapeutic AreaConditionPhase
Congenital, familial and genetic disordersIchthyosis✓ Approved
Skin and subcutaneous tissue disordersPruritus✓ Approved
General disorders and administration site conditionsXerosis✓ Approved

Related Research Articles

PubMedPediatric research2026-08-30

Serum and urinary D-lactate in pediatric intestinal failure: clinical associations and reference values.

Halašová Rita R, Ibrahim Rana R, Balogová Stanislava S, Štichhauer Radek R et al.

D-lactate, produced by intestinal microbiota or derived from the methylglyoxal pathway and diet, is converted by D-lactate dehydrogenase (LDHD) to pyruvate, with several known pathogenic variants of the gene. This study compared serum and urinary D-lactate concentrations across five patient groups and established reference values in healthy children. In this cross-sectional study, 341 serum and urine samples from 129 pediatric patients were analyzed. The cohort comprised patients receiving home parenteral nutrition (PN, n = 19), after bowel adaptation (ADAPT, n = 28), with gastrostomy feeding (PEG, n = 13), other gastrointestinal disorders (GI, n = 14), and healthy controls (HC, n = 55). D-lactate was measured via enzymatic spectrophotometric assay. A genetic sub-analysis assessed pathogenic LDHD variants. Median serum and urinary D-lactate concentrations in healthy controls were 28.5 μmol/L (IQR 25-34.25) and 400 μmol/L (IQR 193-722), respectively. Both serum (p < 0.001) and urine (p = 0.011) D-lactate concentrations were higher in the ADAPT group compared to healthy controls. No pathogenic LDHD variants were identified. Children after bowel adaptation have higher serum and urine D-lactate concentrations compared to healthy controls. Reference values for serum and urinary D-lactate were defined. This is the first study to provide reference values for serum and urinary D-lactate concentrations in healthy children (serum: 28.5 µmol/L (IQR: 25-34.25 µmol/L); urine: 400 µmol/L (IQR: 193-722 µmol/L)). Children after bowel adaptation exhibited higher D-lactate concentrations in both serum and urine compared to healthy controls. Higher serum and urinary D-lactate levels were associated with the presence of an intestinal anastomosis.

PMID 42668282
Read full article →
PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-08-30

AARS1-Mediated H3K27 Lactylation Rewires Glycolysis to Sustain Aggressive and Recurrent Bladder Cancer.

Yuan Qin Q, Song Tianbao T, He Yipeng Y, Xia Sihan S et al.

Recurrence and progression remain major clinical challenges in bladder cancer (BC), yet the mechanisms linking glycolysis to persistent malignant states remain incompletely defined. Here, we identify alanyl tRNA synthetase 1 (AARS1) as a clinically relevant driver of aggressive and recurrent BC. AARS1 is upregulated in BC tissues, enriched in muscle invasive and recurrent tumors, and associated with unfavorable survival. Functionally, AARS1 promotes proliferation, epithelial mesenchymal transition, invasion, apoptosis resistance, tumor growth, and lung colonization. Mechanistically, AARS1 enhances phosphoinositide 3 kinase (PI3K) pathway output, glycolytic flux, and lactate production. Increased lactate availability is linked to histone H3 lysine 27 lactylation (H3K27la) enrichment at the hexokinase 2 (HK2) promoter, increased chromatin accessibility, and HK2 transcriptional activation, supporting an HK2 centered metabolic and epigenetic reinforcement program. HK2 perturbation attenuates AARS1 associated glycolytic and malignant phenotypes. Through structure guided screening and surface plasmon resonance validation, we further identified eltrombopag as an AARS1 binding compound that pharmacologically suppressed the AARS1 associated PI3K, glycolysis, lactate, H3K27la, and HK2 program and restrained tumor progression in preclinical models. These findings define an AARS1 associated metabolic and epigenetic program in BC and nominate AARS1 targeting strategies as a direction for further therapeutic development.

PMID 42669592
Read full article →
PubMediScience2026-08-30

Contrasting chemical characteristics and secondary formation of PM2.5 from mountain and urban sites in central China.

Ren Lihong L, Li Hong H, Chen Shuang S, Zhang Renjian R et al.

The vertical distribution of aerosol is critical to understand the effect of aerosol on climate. This work explored chemical characteristics of PM2.5 at three urban and one mountain sites in Shiyan located in central China. Annual PM2.5 mass concentrations at the mountain site were 70% of urban levels. The total of sulfate, nitrate, and ammonium (SNA) dominated PM2.5, showing higher proportion (49.3%) at mountain site. SNA shows the homogeneous vertical distribution in spring, summer, and autumn with coefficient of divergences below 0.2, whereas most of components were more abundant at urban sites in winter. Higher nitrogen oxidation ratio (0.27) and ratio of secondary organic carbon to organic carbon (0.65) indicated that the aerosol in mountainous atmosphere exhibited a greater degree of aging compared to that at urban sites. These findings enhance our understanding of the vertical distribution of PM2.5 composition and provide a scientific foundation for regional atmospheric pollution control.

PMID 42668565
Read full article →
PubMedCureus2026-08-30

Prognostic Factors Associated With Mortality in Adult Hemophagocytic Lymphohistiocytosis: A Systematic Review and Meta-Analysis.

Osman Elsayed Shaza Bakri SB, Atitalla Hoyam H, Ahmed Salma Elrayah Yousif SEY, Gomaa Abdelfattah Mohamed Kamal MK et al.

Adult hemophagocytic lymphohistiocytosis (HLH) carries a high case-fatality rate, yet reported prognostic factors are discordant and have never been pooled. The aim of this study was to perform the first systematic review and meta-analysis of prognostic factors for mortality in adult HLH. PubMed/MEDLINE, Embase, Web of Science, and the Cochrane Library were searched (from database inception to February 15, 2026) for observational cohort studies of adults (≥18 years) with HLH diagnosed by the HLH-2004 criteria and/or the HScore, reporting mortality against at least one candidate prognostic factor. Risk of bias was appraised using the Quality In Prognosis Studies (QUIPS) tool, and certainty using GRADE. Random-effects meta-analyses (DerSimonian-Laird with Hartung-Knapp correction) were pre-specified for factors reported in at least three cohorts. Reporting followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020. A total of 18 cohorts (3,570 adults) were included. Pooled mortality was 49.5% (95% CI: 41.1-57.8), rising from 34.4% (29.0-40.0) within 30 days to 57.3% (47.9-66.4) at longest follow-up (p<0.001). Malignancy-associated HLH carried higher mortality than other triggers (47.1% vs. 32.2%; 12 cohorts, n=2,373; pooled odds ratio 2.53, 95% CI: 1.55-4.12; I²=66.7%). Older age (2.23, 95% CI: 1.57-3.15; I²=0%), hyperferritinemia (3.07, 95% CI: 1.07-8.82), and elevated lactate dehydrogenase (2.02, 95% CI: 1.05-3.88) independently predicted death; thrombocytopenia and prolonged activated partial thromboplastin time were directionally harmful but imprecise. Egger's test indicated small-study effects (p=0.014). Certainty was low to moderate. Approximately half of adults with HLH die following diagnosis, with nearly one-third of deaths occurring within 30 days. A malignant trigger approximately doubles the odds of death; age, ferritin, and lactate dehydrogenase add independent information. Prospective, multinational registry data with pre-specified thresholds are needed.

PMID 42668817
Read full article →
PubMedCureus2026-08-30

Automatic Frequent Measurements of Plasma Sodium, Potassium, Total Carbon Dioxide, Urea Nitrogen, and Other Values During Hemodialysis.

Lew Susie Q SQ, Ing Todd S TS, Sam Ramin R, Pham Susie N SN et al.

Customizing acute and chronic hemodialysis treatments by tailoring the prescription can occur by knowing the patient's electrolyte and acid-base status at any given moment. Point-of-care (POC) testing using whole blood samples can provide laboratory results of sodium, potassium, chloride, bicarbonate, glucose, calcium, phosphorus, blood urea nitrogen, creatinine, pH, partial pressure of carbon dioxide, oxygen, and lactate. The impact of dialysis on these values will impact patient outcomes and quality of life. Besides knowing the laboratory results, one can calculate the anion gap and osmolar gap to treat patients with disorders such as diabetic ketoacidosis and alcohol poisoning, respectively. We describe a new technology for obtaining blood samples from the hemodialysis arterial line and using a POC device installed in the dialysis machine to perform electrolyte and blood gas measurements, and inform the clinician promptly of possible prescription adjustments to meet the needs of the patient requiring acute or chronic hemodialysis. Besides the obvious benefits, we highlight some pitfalls associated with using whole blood versus serum samples, and arterial versus venous blood samples.

PMID 42669024
Read full article →
PubMedJournal of chromatography. B, Analytical technologies in the biomedical and life sciences2026-08-30

Development and ICH M10-compliant validation of an LC-MS/MS method for quantification of atirmociclib in mouse plasma and its application to preclinical pharmacokinetic studies.

Gaur Ashwani A, Patel Urvesh U, Gavali Ashutosh A, Sekar Sasikumar S et al.

Atirmociclib is a selective cyclin-dependent kinase 4 (CDK4) inhibitor currently under clinical investigation for the treatment of advanced malignancies, particularly hormone receptor positive (HR+) or human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Here, we report the first validated liquid chromatography tandem mass spectrometry (LC-MS/MS) bioanalytical method for the quantification of atirmociclib in mouse plasma, validated in compliance with international council for harmonisation-M10 (ICH-M10) guidelines. Sample preparation involved a rapid and straightforward protein precipitation approach using acetonitrile, yielding consistent recovery (>80%) across low to high concentration levels. Chromatographic separation was achieved on a Kinetex C18 column (50 mm length × 2.1 mm internal diameter, 5 μm particle size) using gradient elution with 5 mM ammonium acetate in water (mobile phase A) and 0.1% v/v formic acid in acetonitrile (mobile phase B). The analyte (atirmociclib) and internal standard (warfarin) were detected using Q1/Q3 (m/z) mass transitions 464.2/303.9 and 309.0/163.0 respectively. The method demonstrated excellent selectivity, accuracy, precision, and linearity over a concentration range of 1-1000 ng/mL. Additionally, reliable quantification was maintained for samples exceeding the upper limit of quantification following up to 10-fold dilution. All validation parameters, including stability in biological matrices and solution, met the predefined acceptance criteria. This sensitive, and reproducible method was successfully applied to support preclinical pharmacokinetic study of atirmociclib in mouse, providing a valuable analytical tool.

PMID 42669270
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about ammonium lactate